See more : Colibri Resource Corporation (CRUCF) Income Statement Analysis – Financial Results
Complete financial analysis of APx Acquisition Corp. I (APXI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of APx Acquisition Corp. I, a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Vanta Bioscience Limited (VANTABIO.BO) Income Statement Analysis – Financial Results
- IHI Corporation (IHICY) Income Statement Analysis – Financial Results
- Excellence Commercial Property & Facilities Management Group Limited (6989.HK) Income Statement Analysis – Financial Results
- GoviEx Uranium Inc. (0UYS.L) Income Statement Analysis – Financial Results
- Thai Wacoal Public Company Limited (WACOAL.BK) Income Statement Analysis – Financial Results
APx Acquisition Corp. I (APXI)
About APx Acquisition Corp. I
APx Acquisition Corp. I. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Mexico City, Mexico.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.74M | 1.12M | 0.00 |
| Gross Profit | -1.74M | -1.12M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 1.74M | 1.12M | 788.61K |
| Other Expenses | 0.00 | 1.12M | 788.61K |
| Operating Expenses | 0.00 | 1.12M | 788.61K |
| Cost & Expenses | 1.74M | 1.12M | 788.61K |
| Interest Income | 3.94M | 2.00M | 1.34K |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.74M | 1.12M | 1.18M |
| EBITDA | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.74M | -1.12M | -788.61K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.00M | 13.96M | 2.44M |
| Income Before Tax | 4.26M | 12.84M | 1.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -13.96M | -2.44M |
| Net Income | 4.26M | 13.41M | 1.66M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | 0.53 | 1.85 | 0.28 |
| EPS Diluted | 0.53 | 1.85 | 0.28 |
| Weighted Avg Shares Out | 8.02M | 7.25M | 5.87M |
| Weighted Avg Shares Out (Dil) | 8.02M | 7.25M | 5.87M |
APX Acquisition Corp. I Announces Nasdaq Delisting Notification for Warrants and Units
NASHVILLE, Tenn. , Nov. 1, 2024 /PRNewswire/ -- As previously announced, on September 4, 2024, APX Acquisition Corp. I (NASDAQ: APXI ) (the "Company"), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating...
APX Acquisition Corp. I Reports 10-K Delinquency Notice
NASHVILLE, Tenn. , June 5, 2024 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI ) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on May 30, 2024 from the Listing Qualifications Department...
APx Acquisition Corp. I, OmnigenicsAI Corp and MultiplAI Health Ltd enter into Business Combination Agreement to create a global AI-driven genomics platform
NASHVILLE, Tenn. , March 26, 2024 /PRNewswire/ -- APx Acquisition Corp. I (NASDAQ: APXI) ("APx"), a publicly traded special purpose acquisition company, OmnigenicsAI Corp ("OmnigenicsAI"), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd ("MultiplAI"), a...
APX Acquisition Corp. I receives Nasdaq notice on late filing of its Form 10-Q
NASHVILLE, Tenn., Dec. 28, 2023 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on December 21, 2023 from the Listing Qualifications Department of The...
APX Acquisition Corp. I & Bioceres Group Announce Letter of Intent for a Business Combination with a Precision Medicine Diagnostic and Wellness Services Company
NASHVILLE, Tenn. , Dec. 1, 2023 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, announced today that it has signed a non-binding letter of intent ("LOI") for a proposed business combination (the...
Source: https://incomestatements.info
Category: Stock Reports